Effect of peptide YY on hepatic fibrosis in rats.
- Author:
Dan-ping SONG
1
;
Lei DONG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Carbon Tetrachloride; Immunohistochemistry; Liver Cirrhosis, Experimental; chemically induced; drug therapy; metabolism; Male; Peptide YY; therapeutic use; Random Allocation; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; biosynthesis
- From: Journal of Southern Medical University 2008;28(7):1261-1263
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the therapeutic effects of peptide YY against hepatic fibrosis in rats and explore the possible mechanism.
METHODRat models of hepatic fibrosis were established with a subcutaneous injection of carbon tetrachloride and randomized into normal control group, model group, peptide YY (PYY)-treated group, octreotide-treated group, and interferon gamma-treated group. Serum levels of the hepatic function indices and hepatic fibrotic index were detected, and the hepatic fibrosis grade was assessed using HE staining. The expression of transforming growth factor beta1 (TGFbeta1) were determined with immunohistochemical staining method.
RESULTSThe rats in PYY-treated group showed significantly different serum levels of TBIL, HA and LN from the rats in the model group (P<0.05). PYY significantly reduced hepatic fibrosis scores and lowered TGFbeta1 expression as compared with the model group.
CONCLUSIONSPYY can down-regulate TGFbeta1 expression to inhibit the development of hepatic fibrosis with comparable efficacy with interferon gamma and octreotide.
